Adoptive immunotherapy using genetically targeted T-cells has recently begun to achieve
impressive clinical impact in selected tumor types. Furthermore, long-term follow-up studies
indicate thus far that integrating viral vectors do not elicit clinically evident genotoxicity in T-
cells, unlike hematopoietic stem cells. The optimism engendered by this clinical experience
provides a platform for consideration of the extended use of this technology in other disease
types. One area of particular interest entails the harnessing of regulatory T-cells (Tregs) in …